NEUROBIOQUÍMICA
Publications (42) Publications in which a researcher has participated
2024
-
A proteomic approach supports the clinical relevance of TAT-Cx43266-283 in glioblastoma
Translational Research, Vol. 272, pp. 95-110
-
Compensatory activity of the PC-ME1 metabolic axis underlies differential sensitivity to mitochondrial complex I inhibition
Nature Communications , Vol. 15, Núm. 1
-
EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models
Neuro-Oncology, Vol. 26, Núm. 7, pp. 1230-1246
2023
-
Antiproliferative effect of boldine on neural progenitor cells and on glioblastoma cells
Frontiers in Neuroscience, Vol. 17
-
Impact of reflex locomotion and the Bobath concept on clinical and biomolecular parameters in people with multiple sclerosis: study protocol for a randomized controlled trial
Frontiers in Neurology, Vol. 14
-
Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
Journal of Visualized Experiments, Vol. 2023, Núm. 196
-
Metabolic remodeling in astrocytes: Paving the path to brain tumor development
Neurobiology of Disease, Vol. 188
2022
-
Src: coordinating metabolism in cancer
Oncogene, Vol. 41, Núm. 45, pp. 4917-4928
2021
-
Efecto de la región de conexina43 inhibidora de Src en células madre de cáncer de pulmón
VII Jornadas de investigadoras de Castilla y León [Recurso electrónico]: la aventura de la ciencia y la tecnología (Fundación 3CIN), pp. 51
-
Efecto del péptido antitumoral TAT-Cx43266-283 en células madre neurales en un modelo de glioma in vivo
VII Jornadas de investigadoras de Castilla y León [Recurso electrónico]: la aventura de la ciencia y la tecnología (Fundación 3CIN), pp. 84
-
Erratum to “Targeting metabolic plasticity in glioma stem cells in vitro and in vivo through specific inhibition of c-Src by TAT-Cx43266-283” [EBioMedicine 62, December 2020] DOI: https://doi.org/10.1016/j.ebiom.2020.103134 (EBioMedicine (2020) 62, (S2352396420305107), (10.1016/j.ebiom.2020.103134))
EBioMedicine
-
Erratum: Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo (Neuro-Oncology DOI: 10.1093/neuonc/noz243)
Neuro-Oncology
-
Impairment of autophagic flux participates in the antitumor effects of tat-cx43266-283 in glioblastoma stem cells
Cancers, Vol. 13, Núm. 17
-
Purinergic receptor blockade with suramin increases survival of postnatal neural progenitor cells in vitro
International Journal of Molecular Sciences, Vol. 22, Núm. 2, pp. 1-14
-
Péptidos penetrantes para atacar al glioma y su microambiente
VII Jornadas de investigadoras de Castilla y León [Recurso electrónico]: la aventura de la ciencia y la tecnología (Fundación 3CIN), pp. 50
-
Recent advances on immunosuppressive drugs and remyelination enhancers for the treatment of multiple sclerosis
Current Pharmaceutical Design, Vol. 27, Núm. 30, pp. 3273-3280
-
geno5mC: A Database to Explore the Association between Genetic Variation (SNPs) and CpG Methylation in the Human Genome
Journal of Molecular Biology, Vol. 433, Núm. 11
2020
-
Christian Giaume (November 1951-July 2019)
Glia, Vol. 68, Núm. 7, pp. 1321-1328
-
Connexin43 peptide, TAT-Cx43266-283, selectively targets glioma cells, impairs malignant growth, and enhances survival in mouse models in vivo
Neuro-Oncology, Vol. 22, Núm. 4, pp. 493-504
-
Connexin43 region 266–283, via src inhibition, reduces neural progenitor cell proliferation promoted by egf and fgf-2 and increases astrocytic differentiation
International Journal of Molecular Sciences, Vol. 21, Núm. 22, pp. 1-22